ERBB2 and gastric cancer: Here, we examined the expression of FASN and the functional involvement of FASN upregulation in HER2+ GC preclinical models and patients and sought to determine whether FASN inhibition is capable of overcoming anti-HER2 treatment resistance in HER2 + GC, mainly by targeting its CSCs.